Comprehensive chromosome analysis in diminished ovarian reserve patients

Zexu Jiao; Orhan Bukulmez

doi:10.1007/978-3-030-23235-1_24

Comprehensive chromosome analysis in diminished ovarian reserve patients

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Aneuploidy is a major source of adverse outcomes in human reproduction. Comprehensive chromosome analysis, now termed preimplantation genetic testing for aneuploidy (PGT-A), involves in vitro fertilization (IVF), embryo biopsy, diagnosis, and selective chromosomally normal embryo transfer and aims to improve IVF success. Currently, there are limited data on PGT-A implementation in patients with diminished ovarian reserve. In this chapter, we will provide an overview of approaches for embryo biopsy, applied diagnostic technologies, and clinical outcomes and discuss the benefit and risk of the implementing PGT-A on diminished ovarian reserve patients.

Original language	English (US)
Title of host publication	Diminished Ovarian Reserve and Assisted Reproductive Technologies
Subtitle of host publication	Current Research and Clinical Management
Publisher	Springer International Publishing
Pages	289-298
Number of pages	10
ISBN (Electronic)	9783030232351
ISBN (Print)	9783030232344
DOIs	https://doi.org/10.1007/978-3-030-23235-1_24
State	Published - Jan 1 2019

Keywords

Aneuploidy screening
Diminished ovarian reserve
In vitro fertilization
Poor responder
Preimplantation genetic testing

ASJC Scopus subject areas

General Health Professions
General Medicine

Access to Document

10.1007/978-3-030-23235-1_24

Cite this

@inbook{19bc20424c4440f9b846d660ed058a13,

title = "Comprehensive chromosome analysis in diminished ovarian reserve patients",

abstract = "Aneuploidy is a major source of adverse outcomes in human reproduction. Comprehensive chromosome analysis, now termed preimplantation genetic testing for aneuploidy (PGT-A), involves in vitro fertilization (IVF), embryo biopsy, diagnosis, and selective chromosomally normal embryo transfer and aims to improve IVF success. Currently, there are limited data on PGT-A implementation in patients with diminished ovarian reserve. In this chapter, we will provide an overview of approaches for embryo biopsy, applied diagnostic technologies, and clinical outcomes and discuss the benefit and risk of the implementing PGT-A on diminished ovarian reserve patients.",

keywords = "Aneuploidy screening, Diminished ovarian reserve, In vitro fertilization, Poor responder, Preimplantation genetic testing",

author = "Zexu Jiao and Orhan Bukulmez",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2020.",

year = "2019",

month = jan,

day = "1",

doi = "10.1007/978-3-030-23235-1_24",

language = "English (US)",

isbn = "9783030232344",

pages = "289--298",

booktitle = "Diminished Ovarian Reserve and Assisted Reproductive Technologies",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Comprehensive chromosome analysis in diminished ovarian reserve patients

AU - Jiao, Zexu

AU - Bukulmez, Orhan

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2020.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aneuploidy is a major source of adverse outcomes in human reproduction. Comprehensive chromosome analysis, now termed preimplantation genetic testing for aneuploidy (PGT-A), involves in vitro fertilization (IVF), embryo biopsy, diagnosis, and selective chromosomally normal embryo transfer and aims to improve IVF success. Currently, there are limited data on PGT-A implementation in patients with diminished ovarian reserve. In this chapter, we will provide an overview of approaches for embryo biopsy, applied diagnostic technologies, and clinical outcomes and discuss the benefit and risk of the implementing PGT-A on diminished ovarian reserve patients.

AB - Aneuploidy is a major source of adverse outcomes in human reproduction. Comprehensive chromosome analysis, now termed preimplantation genetic testing for aneuploidy (PGT-A), involves in vitro fertilization (IVF), embryo biopsy, diagnosis, and selective chromosomally normal embryo transfer and aims to improve IVF success. Currently, there are limited data on PGT-A implementation in patients with diminished ovarian reserve. In this chapter, we will provide an overview of approaches for embryo biopsy, applied diagnostic technologies, and clinical outcomes and discuss the benefit and risk of the implementing PGT-A on diminished ovarian reserve patients.

KW - Aneuploidy screening

KW - Diminished ovarian reserve

KW - In vitro fertilization

KW - Poor responder

KW - Preimplantation genetic testing

UR - http://www.scopus.com/inward/record.url?scp=85085828255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085828255&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-23235-1_24

DO - 10.1007/978-3-030-23235-1_24

M3 - Chapter

AN - SCOPUS:85085828255

SN - 9783030232344

SP - 289

EP - 298

BT - Diminished Ovarian Reserve and Assisted Reproductive Technologies

PB - Springer International Publishing

ER -

Comprehensive chromosome analysis in diminished ovarian reserve patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this